Several preclinical studies have suggested that GLP-1 agonists show anti-inflammatory effects and might show pulmonary inflammation in rat studies with induction of experimental lung injury [168] and respiratory syncytial virus (RSV) infection [169]. The gene discussed is GLP1R; the disease is inflammatory response.